SCHEMBL8735979

SCHEMBL8735979

c1cc(-c2cccc(-n3c4ccccc4c4cnccc43)c2)cc(-c2c3ccccc3c(-c3ccc4ccccc4c3)c3ccccc23)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.44
CYP19A1 P11511 1/20 0.44
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
MAOA P21397 4/20 0.38
MAOB P27338 4/20 0.38
ACHE P22303 1/20 0.38
MAPK9 P45984 5/20 0.38
MAPK10 P53779 5/20 0.38
MAPK8 P45983 2/20 0.38
GRM1 Q13255 1/20 0.36
SIRT2 Q8IXJ6 4/20 0.36
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8735538 0.98 CYP11B1 (0.43) CYP17A1CYP19A1CYP11B1CYP11B2MAOA
SCHEMBL12442658 0.96 CYP17A1 (0.42) CYP17A1CYP19A1CYP11B1CYP11B2MAOA
SCHEMBL8737078 0.93 CYP11B1 (0.42) CYP17A1CYP19A1CYP11B1CYP11B2MAPK9
SCHEMBL8737594 0.92 CYP11B2 (0.44) CYP17A1CYP19A1CYP11B1CYP11B2MAOA
SCHEMBL6114143 0.92 CYP17A1 (0.43) CYP17A1CYP19A1CYP11B1CYP11B2MAPK9
SCHEMBL12169028 0.91 CYP17A1 (0.44) CYP17A1CYP19A1CYP11B1CYP11B2MAPK9
SCHEMBL12168981 0.91 CYP17A1 (0.44) CYP17A1CYP19A1CYP11B1CYP11B2MAPK9
SCHEMBL6114117 0.91 MAPK10 (0.42) CYP17A1CYP19A1CYP11B1CYP11B2MAOA
SCHEMBL6113914 0.90 CYP11B1 (0.40) CYP17A1CYP19A1CYP11B1CYP11B2MAOA
SCHEMBL8736819 0.90 CYP11B1 (0.43) CYP17A1CYP19A1CYP11B1CYP11B2MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9755152-B2 Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2017-09-05 US disclosed
US-9755152-B2 Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2017-09-05 US disclosed
US-20150155496-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO LTD (JP) 2015-06-04 US disclosed
US-20150155496-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO LTD (JP) 2015-06-04 US disclosed
US-8927119-B2 Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2015-01-06 US disclosed
US-8927119-B2 Compound having substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2015-01-06 US disclosed
US-20120126220-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO., LTD. (JP) 2012-05-24 US disclosed
US-20120126220-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO., LTD. (JP) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150155496-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE SLCO2B1, PNPO, SLCO2A1 CYP17A1 652/4885CYP19A1 334/4885CYP11B1 793/4885
US-20120126220-A1 COMPOUND HAVING SUBSTITUTED ANTHRACENE RING STRUCTURE AND PYRIDOINDOLE RING STRUCTURE, AND ORGANIC ELECTROLUMINESCENT DEVICE SLCO2B1, PNPO, SLCO2A1 CYP17A1 652/4885CYP19A1 334/4885CYP11B1 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.